Login Register Cart 0
Review Article

脂肪细胞脂肪酸结合蛋白（A-FABP）是治疗肥胖相关癌症的潜在新靶点

卷 23, 期 6, 2022

发表于: 12 July, 2021

页: [597 - 605] 页: 9

弟呕挨: 10.2174/1389450122666210712193654

价格: $65

摘要

脂肪酸结合蛋白A（A-FABP）是主要存在于脂肪组织和巨噬细胞中的FABPs亚型之一。它通过多种综合途径发挥作用，调节炎症和脂质代谢，促进葡萄糖生成，损害胰岛素功能，并促进动脉粥样硬化和糖尿病等疾病。A-FABP在肥胖患者的脂肪组织中上调，其释放到血液中的增加与体重指数呈正相关。因此，A-FABP在肥胖人群的代谢调节中起着关键作用。最近对小鼠模型和人类的研究表明，A-FABP在增加肥胖相关癌症风险方面的作用。本文就肥胖、癌症与A-FABP作为肥胖相关癌症新的潜在治疗靶点的关系的研究现状进行综述。

关键词: 脂肪酸结合蛋白，脂肪细胞，癌症，肥胖，代谢综合征，代谢。

« Previous Next »
图形摘要

[1]
Kucharski M, Kaczor U. Fatty acid binding protein 4 (FABP4) and the body lipid balance. Folia Biol 2017; 65(4): 181-6.
[http://dx.doi.org/10.3409/fb65_4.181]
[2]
Harasim E, Kalinowska A, Stępek T, Chabowski A. Udział białek transportujących (FAT / CD36, FABPpm, FATP) w metabolizmie lipidów w mięśniach szkieletowych The role of fatty-acid transport proteins (FAT / CD36, FABPpm, FATP) in lipid metabolism in skeletal muscles. Postep Hig Med Dosw Online 2008; 433-41.
[3]
Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 2002; 59(7): 1096-116.
[http://dx.doi.org/10.1007/s00018-002-8490-y] [PMID: 12222958]
[4]
Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H, Scheffold T. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010; 105(1): 1-9.
[http://dx.doi.org/10.1016/j.amjcard.2009.08.645] [PMID: 20102882]
[5]
Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept 2008; 147(1-3): 25-8.
[http://dx.doi.org/10.1016/j.regpep.2007.12.002] [PMID: 18201778]
[6]
Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009; 32(1): 147-52.
[http://dx.doi.org/10.2337/dc08-1379] [PMID: 18835952]
[7]
Engl J, Ciardi C, Tatarczyk T, et al. A-FABP-a biomarker associated with the metabolic syndrome and/or an indicator of weight change? Obesity (Silver Spring) 2008; 16(8): 1838-42.
[http://dx.doi.org/10.1038/oby.2008.273] [PMID: 18535557]
[8]
Zeng J, Sauter ER, Li B. FABP4: A new player in obesity-associated breast cancer. Trends Mol Med 2020; 26(5): 437-40.
[http://dx.doi.org/10.1016/j.molmed.2020.03.004] [PMID: 32359475]
[9]
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20(2): 12.
[http://dx.doi.org/10.1007/s11906-018-0812-z] [PMID: 29480368]
[10]
Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. Int J Obes 2011; 35(3): 393-400.
[http://dx.doi.org/10.1038/ijo.2010.152] [PMID: 20680014]
[11]
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
[http://dx.doi.org/10.1016/S0140-6736(05)66378-7] [PMID: 15836891]
[12]
Wagh A, Stone NJ. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther 2004; 2(2): 213-28.
[http://dx.doi.org/10.1586/14779072.2.2.213] [PMID: 15151470]
[13]
Gormez S, Erdim R, Akan G, et al. Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome. Cardiovasc Pathol 2020; 46: 107192.
[http://dx.doi.org/10.1016/j.carpath.2019.107192] [PMID: 31927390]
[14]
Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1(2): 107-19.
[http://dx.doi.org/10.1016/j.cmet.2004.12.008] [PMID: 16054052]
[15]
Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs-mechanisms and therapeutic implications. Nat Rev Endocrinol 2015; 11(10): 592-605.
[http://dx.doi.org/10.1038/nrendo.2015.122] [PMID: 26260145]
[16]
Prentice KJ, Saksi J, Hotamisligil GS. Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses. J Lipid Res 2019; 60(4): 734-40.
[http://dx.doi.org/10.1194/jlr.S091793] [PMID: 30705117]
[17]
Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues. Diabetes 2014; 63(3): 900-11.
[http://dx.doi.org/10.2337/db13-0436] [PMID: 24319114]
[18]
Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 2000; 275(24): 18527-33.
[http://dx.doi.org/10.1074/jbc.M001297200] [PMID: 10748014]
[19]
Tryggestad JB, Teague AM, Sparling DP, Jiang S, Chernausek SD. Macrophage-derived microrna-155 increases in obesity and influences adipocyte metabolism by targeting peroxisome proliferator-activated receptor gamma. Obesity 2019; 27(11): 1856-64.
[http://dx.doi.org/10.1002/oby.22616] [PMID: 31531958]
[20]
Chow WS, Tso AWK, Xu A, et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. J Am Heart Assoc 2013; 2(1): e004176.
[http://dx.doi.org/10.1161/JAHA.112.004176] [PMID: 23525430]
[21]
Tso AWK, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30(10): 2667-72.
[http://dx.doi.org/10.2337/dc07-0413] [PMID: 17620449]
[22]
Yamashita K, Yamamoto MH, Igawa W, et al. Association of epicardial adipose tissue volume and total coronary plaque burden in patients with coronary artery disease. Int Heart J 2018; 59(6): 1219-26.
[http://dx.doi.org/10.1536/ihj.17-709] [PMID: 30369579]
[23]
Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447(7147): 959-65.
[http://dx.doi.org/10.1038/nature05844] [PMID: 17554340]
[24]
Furuhashi M, Yuda S, Muranaka A, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J 2018; 82(4): 1121-9.
[http://dx.doi.org/10.1253/circj.CJ-17-1295] [PMID: 29445067]
[25]
Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. NNat Med 2001; 7(6): 699-705.
[26]
Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10(8): 455-65.
[http://dx.doi.org/10.1038/nrendo.2014.94] [PMID: 24935119]
[27]
Quispe-Tintaya W. HHS public access. Physiol Behav 2017; 176(3): 139-48.
[28]
Hao J, Zhang Y, Yan X, et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab 2018; 28(5): 689-705.e5.
[http://dx.doi.org/10.1016/j.cmet.2018.07.006] [PMID: 30100196]
[29]
Cui Y, Song M, Kim SY. Prognostic significance of fatty acid binding protein-4 in the invasive ductal carcinoma of the breast. Pathol Int 2019; 69(2): 68-75.
[http://dx.doi.org/10.1111/pin.12756] [PMID: 30694572]
[30]
Tucker SL, Gharpure K, Herbrich SM, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 2014; 20(12): 3280-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0445] [PMID: 24756370]
[31]
Gharpure KM, Pradeep S, Sans M, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 2018; 9(1): 2923.
[http://dx.doi.org/10.1038/s41467-018-04987-y] [PMID: 30050129]
[32]
Mukherjee A, Chiang CY, Daifotis HA, et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res 2020; 80(8): 1748-61.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-1999] [PMID: 32054768]
[33]
Chiyonobu N, Shimada S, Akiyama Y, et al. Fatty acid binding protein 4 (fabp4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors. Am J Pathol 2018; 188(5): 1213-24.
[http://dx.doi.org/10.1016/j.ajpath.2018.01.012] [PMID: 29454748]
[34]
Laouirem S, Sannier A, Norkowski E, et al. Endothelial fatty liver binding protein 4: A new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene 2019; 38(16): 3033-46.
[http://dx.doi.org/10.1038/s41388-018-0597-1] [PMID: 30575815]
[35]
Thompson KJ, Austin RG, Nazari SS, Gersin KS, Iannitti DA, McKillop IH. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int 2018; 38(6): 1074-83.
[http://dx.doi.org/10.1111/liv.13639] [PMID: 29171144]
[36]
Nie J, Zhang J, Wang L, et al. Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. J Exp Clin Cancer Res 2017; 36(1): 183.
[http://dx.doi.org/10.1186/s13046-017-0641-y] [PMID: 29237483]
[37]
Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11(12): 886-95.
[http://dx.doi.org/10.1038/nrc3174] [PMID: 22113164]
[38]
Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochim Biophys Acta 2011; 1807(6): 664-78.
[http://dx.doi.org/10.1016/j.bbabio.2010.11.004] [PMID: 21111705]
[39]
Freeman. HHS public access. Physiol Behav 2018; 176(1): 139-48.
[40]
Uehara H, Takahashi T, Oha M, Ogawa H, Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer 2014; 135(11): 2558-68.
[41]
Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA. Obesity, body composition, and prostate cancer. BMC Cancer 2012; 12.
[42]
Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23(7): 1665-71.
[43]
Kristal AR, Gong Z. Obesity and prostate cancer mortality. Futur Oncol 2007; 3(5): 557-67.
[44]
Celis JE, Østergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996; 56(20): 4782-90.
[PMID: 8840999]
[45]
Ohlsson G, Moreira JMA, Gromov P, Sauter G, Celis JE. Loss of expression of the adipocyte-type fatty acid-binding protein (AFABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 2005; 4(4): 570-81.
[http://dx.doi.org/10.1074/mcp.M500017-MCP200] [PMID: 15734831]
[46]
Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009; 124(8): 1820-8.
[http://dx.doi.org/10.1002/ijc.24112] [PMID: 19115207]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy